about
Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironmentImmunogenicity of coiled-coil based drug-free macromolecular therapeutics.Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free ratsPatterns of early gut colonization shape future immune responses of the host.Heat-induced structural changes affect OVA-antigen processing and reduce allergic response in mouse model of food allergy.Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models.The Microbiota Determines Susceptibility to Experimental Autoimmune UveoretinitisIntestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response.Interaction of mucosal microbiota with the innate immune system.Involvement of innate immunity in the development of inflammatory and autoimmune diseases.Intestinal Microbiota: Facts and Fiction.Development of gut inflammation in mice colonized with mucosa-associated bacteria from patients with ulcerative colitisUrinary Intestinal Fatty Acid-Binding Protein Can Distinguish Necrotizing Enterocolitis from Sepsis in Early Stage of the Disease.Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice.Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.Perinatal period cytokines related to increased risk of future allergy development.Protein microarray analysis as a tool for monitoring cellular autoreactivity in type 1 diabetes patients and their relatives.Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis.Correction: Heat-Induced Structural Changes Affect OVA-Antigen Processing and Reduce Allergic Response in Mouse Model of Food Allergy.Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis.Dual inhibition of nitric oxide and prostaglandin E2 production by polysubstituted 2-aminopyrimidines.Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice.Intestinal inflammation modulates expression of 11beta-hydroxysteroid dehydrogenase in murine gut.Anti-GAD65 reactive peripheral blood mononuclear cells in the pathogenesis of cystic fibrosis related diabetes mellitusThe intestinal fatty acid-binding protein as a marker for intestinal damage in gastroschisisDiet Rich in Animal Protein Promotes Pro-inflammatory Macrophage Response and Exacerbates Colitis in MiceCrucial Role of Microbiota in Experimental Psoriasis Revealed by a Gnotobiotic Mouse ModelCytokine profiling in human colostrum and milk by protein arrayMultiplex analysis of cytokines involved in tumour growth and spontaneous regression in a rat sarcoma modelColostrum of healthy mothers contains broad spectrum of secretory IgA autoantibodiesUrinary I-FABP, L-FABP, TFF-3, and SAA Can Diagnose and Predict the Disease Course in Necrotizing Enterocolitis at the Early Stage of DiseaseThe role of gut microbiota in intestinal and liver diseasesProphylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83Possibilities of therapeutic manipulation of the gut microbiotaGut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiomeInflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial ResponseMicrobiota, immunity and immunologically-mediated diseases
P50
Q21562212-A7966795-3488-4E06-BB70-06D41940545EQ33602669-B2D13A34-461B-4EF5-B50F-7530736A519AQ33797774-1F4530FC-0DFE-4575-9A4A-001858478B3CQ34221994-F022D857-F77C-43A5-A594-ABF6FD280B12Q34281786-6B049C7F-6126-46DF-8DAF-420BEE49F7D7Q35172967-B74055CF-E2BB-40B8-9AE0-F7B06F40218FQ36050092-953A36EA-4B97-4AAC-B50F-C81E9E99D1DFQ36081679-1F9229D6-2D1E-4ECD-900B-58C34F55FEB4Q36161518-9DD7657D-A8AD-4675-AA17-C4DBACBB8EC6Q36242917-BB4984DB-0F66-4653-A47F-3A0C7FFFDD1CQ36266518-286B04A9-300E-469A-9FC7-75C7E83645AEQ36393719-FA4FC198-85DC-4EFC-8D88-99B2F4BC8D7FQ36773550-79319600-2D1B-4D9E-A559-7A8FA3D18C45Q37097054-063F1FB5-981D-497F-8F0C-07C7E7DE415EQ38663475-E77C6AD9-EDFF-4986-818D-A733092884B4Q40120609-E78E97FF-C98C-40FD-8E9D-D2EBB93A4A1BQ42518689-1236B8C7-0BCD-44B5-BFAC-8E55A07F07D7Q44632948-E3D5D2AB-53B0-4B31-8967-A81AADF6F926Q46649526-F6755E05-3ACB-47CB-A314-CF4D4330D71CQ46929114-1EB91CE8-55E7-4CAA-AF14-BE95015BD9D0Q51818416-9CA5F9B0-9406-412C-A7D7-CD5C84994F00Q54197209-1D55EC7A-87FA-4061-987D-E52487A9A330Q54450083-EF3AC7BA-E8C9-4F12-BF5C-B4D83ED5132DQ54572596-6A7DD921-DB3D-423B-9FAC-E14028206FBFQ59234257-36B1FC83-4606-44FB-813D-E949245BE8DBQ61818362-E8F383C8-57F8-4BA7-81B2-A6BD0F5BE2D1Q64084934-BE312566-4521-4AB8-A54C-41E7866513EAQ64118902-DC98FE71-6E95-4FC0-BDFE-8400C9B83305Q79960911-0C824327-970A-48FF-8726-002AC2546554Q80173568-9281E352-72A1-4B0E-BD0A-C48A4DD01B71Q84551708-AFE07D10-4E28-4F2E-9745-DAED3F363D60Q90451647-45284BED-097D-4551-8BE5-919884894988Q90724941-DC443006-CDC1-4F09-872E-8320854A2A7FQ91040881-A3FA7747-2229-499B-82A1-2F22D1B4CC45Q91488537-C75713E5-E70E-45DF-B387-E09A29374DCAQ91827621-F49C7B3B-4FDF-4A6E-AF12-4F51C31D3876Q92129980-D453FC43-A6A5-4C1E-9EB5-57F22AB2EEB0Q92606446-42DEBA91-FE71-46CC-8D96-A06620D30B73
P50
description
mikrobiolog, imunolog
@cs
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Kverka
@ast
M Kverka
@es
M Kverka
@nl
M Kverka
@sl
Miloslav Kverka
@cs
Miloslav Kverka
@en
type
label
M Kverka
@ast
M Kverka
@es
M Kverka
@nl
M Kverka
@sl
Miloslav Kverka
@cs
Miloslav Kverka
@en
prefLabel
M Kverka
@ast
M Kverka
@es
M Kverka
@nl
M Kverka
@sl
Miloslav Kverka
@cs
Miloslav Kverka
@en
P106
P214
3995148390875910830002
P31
P496
0000-0002-1335-5252